Hepatitis B immune globulin is an injection of immunoglobulin G (IgG) antibodies to prevent the development of chronic Hepatitis B infection. Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B.
- Mechanism
- Curator reviewed
In countries with high rates of hepatitis B infection, vaccination of newborns has not only reduced the risk of infection, but has also led to marked reduction in liver cancer.
- Primary indication
- Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications.Curator reviewed · 2 structured indications
- First approval
- Canada, 2012 · United States, 1996 · European Union, 2020
- Also known as
- HBIG · Hepatitis B immune globulin (human) · Hepatitis B immune globulin human · Hepatitis B immune globulin intravenous (human) · Hepatitis B immunoglobulin (human)
- Brand names
Resolves to
Clinical / RWD
Targets
What you can answer from here — as of May 03, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with Hepatitis B immune globulin, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account